Leukotriene receptor antagonists for non-cystic fibrosis bronchiectasis.
BACKGROUND
Leukotriene receptor antagonists are a new class of drug that were initially identified for use in asthma. As they have an effect on neutrophil mediated inflammation, they may be of benefit in bronchiectasis.


OBJECTIVE
To determine whether leukotriene receptor antagonists have any additive benefit over and above conventional treatment for bronchiectasis (usually consisting of antibiotics and postural drainage).


METHODS
The Cochrane Airways Group clinical trials register derived from MEDLINE, EMBASE and hand searching of major journals was searched using the terms:Bronchiec* AND leukotrien* OR anti-leuk* OR cysteinyl, Bronchiec* AND monteluk*, Bronchiec* AND zafirluk*


METHODS
Only randomised, controlled trials were considered


METHODS
The results of searches were analysed by both authors


RESULTS
No randomised, controlled trials were identified


CONCLUSIONS
Further research is required to establish any benefit from the use of leukotriene antagonists in bronchiectasis.
Corless
J A
JA
Aintree Chest Centre, University Hospital, Aintree, Aintree Chest Centre, University Hospital Aintree, Lower Lane, Liverpool, Merseyside, UK, L9 7AL. j.corless@bigfoot.com
Warburton
C J
CJ
D000085:Acetates / Q000627:therapeutic use; D001987:Bronchiectasis / Q000188:drug therapy* / Q000209:etiology; D002986:Clinical Trials as Topic; D003521:Cyclopropanes; D006801:Humans; D007211:Indoles; D020024:Leukotriene Antagonists / Q000627:therapeutic use*; D048448:Phenylcarbamates; D010919:Placebos; D011804:Quinolines / Q000627:therapeutic use; D013440:Sulfides; D013449:Sulfonamides; D014105:Tosyl Compounds / Q000627:therapeutic use
D000085:Acetates; D003521:Cyclopropanes; D007211:Indoles; D020024:Leukotriene Antagonists; D048448:Phenylcarbamates; D010919:Placebos; D011804:Quinolines; D013440:Sulfides; D013449:Sulfonamides; D014105:Tosyl Compounds; C093875:montelukast; C062735:zafirlukast